ClinicalTrials.gg
CompletedNCT05180526Updated Oct 13, 2026

Assessment of Safety , Clinical Efficacy With QLETLI in Non-infectious Uveitis (UV)

A Phase 4 interventional study of QLETLI in Uveitis, sponsored by Bio-Thera Solutions. Completed at 7 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Bio-Thera Solutions · Phase 4, Interventional, and Treatment

How we know

Updated Oct 13, 2026Now CompletedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Uveitis with a site in China — 7 open to participants now, 9 under way, none of them phase 3. Uveitis · China.

Enrollment
7th of 20
60 · median 30
Started
2021
with 4 others
Phase 4
4 of 28
1 open now
Registered
14th of 28
by date
Lead sponsor
1 of 28
Bio-Thera Solutions

Among the 28 studies in Uveitis with a site in China, this one is the 7th largest by enrollment of the 20 interventional ones that give a count, is one of 5 that started in 2021, is one of 4 in phase 4, and was the 14th registered.

Uveitis

300 studies on the registry are indexed under Uveitis; 33 are open to participants now.

Browse Uveitis studies →

Open to participants now

7 of the 28 studies in Uveitis with a site in China are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 23 Uveitis studies recruiting now, 14 (61%) set no upper age limit and 9 (39%) stop at 75 or younger; 10 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Uveitis with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, prospective, post-marketing clinical study with a total of 60 uveitis (UV) subjects planned to be enrolled.

Screening period (-2\~0 weeks) ,Treatment period (1-22 weeks), Follow-up period, At the same time, plasma concentration will be determined

Read the detailed description

This is a multicenter, prospective, post-marketing clinical study with a total of 60 uveitis (UV) subjects planned to be enrolled.

Screening period (-2\~0 weeks) : the inclusion and exclusion criteria were evaluated, and those meeting the criteria could enter the treatment period.

Treatment period (1-22 weeks) : Eligible subjects with non-infectious uveitis were given an initial subcutaneous injection of 80 mg at week 1, followed by a subcutaneous injection of 40 mg of Glorio (adamuzumab injection) every other week from week 1 to week 22 (a total of 12 doses).

Follow-up period: Follow-up for safety and/or efficacy is recommended at 6, 12, 24, and 32 weeks after initiation of the study drug. A final visit will be made at 32 weeks. During the study, if the condition of the subjects or their symptoms and signs become worse, the investigator can adjust the use of drugs for uveitis other than study drugs according to the actual situation of the subjects.

At the same time, plasma concentration will be determined before D1, D78 (week 12), and D162 (week 24); Immunogenicity analysis was performed before D1 administration, before D78 (week 12), before D162 (week 24) and before D218 (week 32)

03

Conditions studied

  • Uveitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients voluntarily participated in the study and signed
  • Aged between 18 and 70 (including threshold), male or female;
  • Diagnosis of non-infectious intermediate, posterior, or total uveitis in at least one eye;
  • Received maintenance therapy (oral prednisone 10-60mg/day or equivalent for ≧2 weeks before screening, and no dose adjustment from screening to baseline;
  • At baseline, at least one eye was diagnosed with active uveitis, presenting as meeting at least one of the following criteria: active inflammatory chorioretinal and/or inflammatory retinal vasculopathy; Cell grade of anterior chamber ≧2+; Degree of vitreous turbid ≧2+;
  • Negative serum pregnancy test results of women of childbearing age during screening visits;

Exclusion criteria

Exclusion Criteria:

  • Patients with the following eye conditions:
  • Patients with simple anterior uveitis;
  • Uveitis with macular edema as the only manifestation;
  • is confirmed or suspected infectious uveitis (including but not limited to the following causes of infectious uveitis, tuberculosis, cytomegalovirus, lyme disease, toxoplasmosis, human, T, Whipple's disease virus type 1 infection, herpes zoster virus and herpes simplex virus) or disguise syndrome (for example: eye trauma, lymphoma, malignant tumor, or surgery, etc.);
  • Uncontrolled glaucoma, defined as intraocular pressure higher than 25 mmHg after drug treatment, or optic nerve damage;
  • Best corrected visual acuity of less than 20 letters in at least one eye at baseline;
  • With other fundus diseases (such as fertile or serious non fertile diabetic retinopathy or diabetic retinopathy with clinical significance of macular edema, retinal vein occlusion, macular degeneration, age, sex, blood vessel patterns change, the pathological myopia, retinal detachment, macular hole, toxoplasmosis, optic nerve disease, etc.);
  • Demyelinating disease (including myelitis and optic neuritis) or a history of neurology suggesting symptoms of demyelinating disease (including but not limited to optic neuritis);
  • Refractive media opacity or pupil failure that significantly interferes with visual acuity detection, anterior segment and fundus assessment;
  • One-eyed patients deemed unsuitable for inclusion by the investigator;
  • Peribulbar, intravitreal or subocular injections were given within 30 days prior to screening;
  • Posterior capsulotomy was performed within 30 days prior to screening;
  • Cataract surgery is expected within 90 days prior to screening or during the study period;
  • An intravitreal injection of anti-VEGF therapy (e.g., raizumab, apecivir, or Combocept) within 90 days prior to baseline;
  • Ozurdex implants (dexamethasone implants) were performed within 6 months prior to baseline;
  • Treatment with intravitreal injection of methotrexate within 90 days prior to baseline;
  • Had been treated with vitreous Retisert (glucocorticoid implant) or had complications with the implant during the 36 months prior to baseline; Removal of Retisert within 90 days prior to baseline or complications of removal.
  • Having any of the following general conditions:
  • Subjects meet any of the following criteria associated with latent or active tuberculosis (TB) infection:

    . A history of active TB ≤ 3 years before screening (but can also be included if it is > 3 years and documented completion of adequate treatment); B. Signs or symptoms suggestive of active TB at the time of screening in the history and/or physical examination; C. Recent close contact with someone with active TB; D. If a TB infection T-cell test is positive at the time of screening, subjects will be excluded from the study if their first TB infection T-cell test is inconclusive. For suitable standards has been completed before screening latent TB treatment and no other risk factors, imaging findings, or support the latent or signs of active TB specific subjects, for positive or uncertain results may be the exception handling, researchers with the qualified physician judgment, tuberculosis (including extrapulmonary) risk, decision and discuss with bidders;

  • Positive antibody during screening; Or antibody positive; Or treponema pallidum antibody positive;
  • Symptoms of severe, progressive or uncontrollable kidney, liver, blood, gastrointestinal, lung, cardiovascular, neurological or brain disease. The investigator felt that participating in the study placed patients at unacceptable risk.
  • Patients with malignant tumors.
  • Patients with moderate to severe heart failure (New York Heart Society Grades 3-4).
  • History of severe allergy or anaphylactoid reaction to monoclonal antibodies.
  • Prior treatment with anti-TUMOR necrosis factor TNF or other biological agents with potential therapeutic effect for uveitis (excluding intravitreal anti-VEGF drugs).
  • During the 30 days prior to baseline, the combined dose of other therapy increased or did not meet any of the following conditions: methotrexate MTX≤25mg/ week; Cyclosporine ≤4 mg/kg/ day; Mycophenolate (or equivalent dose of mycophenolate) ≤2g/ day; Azathioprine ≤175 mg/ day; Tacrolimus oral ≤8 mg/ day.
  • Received clinical trial drug intervention within 3 months prior to screening.
  • Received any within 3 months prior to receiving the first dose of the study drug, or planned to receive live vaccine during the study period.
  • There are to dilatation drugs.
  • Patients judged unsuitable for inclusion by other investigators
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Experimental

    80 mg was given subcutaneously at week 1, followed by 40 mg of Glorio (adamuzumab injection) every other week from week 1 to week 22 (12 doses).

    Drug: QLETLI

Interventions

  • DrugQLETLI

    80 mg was given subcutaneously at week 1, followed by 40 mg of Glorio (adamuzumab injection) every other week from week 1 to week 22 (12 doses).

06

What researchers measure

Primary outcomes

  1. Duration of treatment failure

    Duration of treatment failure at 6 weeks of treatment or between 6 and 24 weeks of treatment (treatment failure is defined as meeting at least one of the following conditions in at least one eye:

    Time frame: 6\12\24week

Secondary outcomes

  1. treatment failure rate

    Treatment failure rate at each visit point from first administration to 24 weeks.Treatment failure was defined as meeting at least one of the following conditions in at least one eye: newly active inflammatory choroiditis or retinal vasculopathy \[from baseline\]; The anterior chamber cell grading or vitreous opacity grading did not reach ≦0.5+ during the 6 weeks visit, or the optimal condition did not improve in all visits after 6 weeks. Best corrected visual acuity decreased by ≧15 letters compared to best condition

    Time frame: 6/12/24week

  2. Changes in ocular inflammation

    changes in anterior chamber cell grade

    Time frame: 6/12/24week

  3. Changes in ocular inflammation

    changes in vitreous turbidity

    Time frame: 6/12/24week

  4. Changes in ocular inflammation

    changes in macular edema

    Time frame: 6/12/24week

  5. Changes in ocular inflammation

    changes in central retinal thickness

    Time frame: 6/12/24week

  6. Changes in visual acuity

    Changes in visual acuity

    Time frame: 6/12/24week

  7. Changes in visual function scale VFQ-25

    Changes in visual function scale VFQ-25

    Time frame: 6/12/24week

07

Study locations

7 sites
  • Peking Union Medical College Hospital
    Beijing, China
  • The Second Xiangya Hospital of Central South University
    Changsha, China
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, China
  • The second hospital of Jilin University
    Jilin City, China
  • Tianjin Medical University Eye Hospital
    Tianjin, China
  • Renmin Hospital of Wuhan University
    Wuhan, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Dec 2021 to primary completion in Aug 2025, 43 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Dec 2024 → Aug 2025 and completion Dec 2024 → Aug 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2021
First posted
Jan 6, 2022
StartActual
Dec 27, 2021
Primary completionActual
Aug 5, 2025was Dec 2024
CompletionActual
Aug 5, 2025was Dec 2024
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 13, 2026
Sites
1 site added, 1 site removed
Show site
  • The second hospital of Jilin University · Jilin City, China
Show 1 removed
  • The second hospital of Jilin University · Jilin, China
Oct 13, 2026
Primary completion
Dec 30, 2024→Aug 5, 2025 (actual)
Oct 13, 2026
Study completion
Dec 30, 2024→Aug 5, 2025 (actual)
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Active, not recruiting→Completed
    1 site added, 1 site removed
    Show site
    • The second hospital of Jilin University · Jilin City, China
    Show 1 removed
    • The second hospital of Jilin University · Jilin, China
    Primary completion Dec 30, 2024→Aug 5, 2025 (now actual)
    Study completion Dec 30, 2024→Aug 5, 2025 (now actual)
    + 4 other changes: identifiers, verification date, oversight details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05180526
Responsible party
Sponsor
First posted
Jan 6, 2022
Start date
Dec 27, 2021
Primary completion
Aug 5, 2025
Completion
Aug 5, 2025
Last update
Oct 13, 2026

Study contacts

Peizeng Yang, M.D
principal investigator · 1 Youyi Road, Yuzhong District, Chongqing, China

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion